121 related articles for article (PubMed ID: 8821952)
1. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
Hirama T; Miller CW; Wilczynski SP; Koeffler HP
Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
3. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
4. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection.
Kim JW; Namkoong SE; Ryu SW; Kim HS; Shin JW; Lee JM; Kim DH; Kim IK
Gynecol Oncol; 1998 Jul; 70(1):75-9. PubMed ID: 9698478
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
7. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of the INK4 family of genes in prostate carcinomas.
Park DJ; Wilczynski SP; Pham EY; Miller CW; Koeffler HP
J Urol; 1997 May; 157(5):1995-9. PubMed ID: 9112579
[TBL] [Abstract][Full Text] [Related]
11. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
12. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines.
Igaki H; Sasaki H; Kishi T; Sakamoto H; Tachimori Y; Kato H; Watanabe H; Sugimura T; Terada M
Biochem Biophys Res Commun; 1994 Sep; 203(2):1090-5. PubMed ID: 8093026
[TBL] [Abstract][Full Text] [Related]
13. [Alteration of p15 and p16 gene in gastric cancer].
Fushida S; Yonemura Y; Kawamura T; Nojima N; Satoh T; Fujita H; Michiwa Y; Fujimura T; Nishimura G; Miwa K; Miyazaki I
Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():279-84. PubMed ID: 9263516
[TBL] [Abstract][Full Text] [Related]
14. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
Miyamoto H; Kubota Y; Fujinami K; Dobashi Y; Kondo K; Yao M; Shuin T; Hosaka M
Oncol Res; 1995; 7(7-8):327-30. PubMed ID: 8747595
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV.
Olshan AF; Weissler MC; Pei H; Conway K; Anderson S; Fried DB; Yarbrough WG
Oncogene; 1997 Feb; 14(7):811-8. PubMed ID: 9047388
[TBL] [Abstract][Full Text] [Related]
17. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
[TBL] [Abstract][Full Text] [Related]
18. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
Liu Q; Yan YX; McClure M; Nakagawa H; Fujimura F; Rustgi AK
Oncogene; 1995 Feb; 10(3):619-22. PubMed ID: 7845688
[TBL] [Abstract][Full Text] [Related]
19. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
20. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas.
Marchetti A; Buttitta F; Pellegrini S; Bertacca G; Chella A; Carnicelli V; Tognoni V; Filardo A; Angeletti CA; Bevilacqua G
J Pathol; 1997 Feb; 181(2):178-82. PubMed ID: 9120722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
